We envision a world where we feel tomorrow is another day.
News
- Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
- Chordia Therapeutics Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd
- Chordia Therapeutics Concludes Basic Agreement on Business Tie up with MEDIPAL HOLDINGS CORPORATION
Science
Company
- Corporate Name
- Chordia Therapeutics Inc.
- Foundation
- November 1, 2017
- Head Office
- 26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-0012 Japan
- Tokyo Office
- 3-11-5,Nihonbashi-honcho,
Chuo-ku,Tokyo 103-0023 Japan
- Representative
- Hiroshi Miyake, Ph.D. CEO
